Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $3.3 million.

  • Lyell Immunopharma's Cash from Investing Activities rose 7460.9% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.0 million, marking a year-over-year increase of 53740.2%. This contributed to the annual value of $122.4 million for FY2024, which is 3348.26% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Cash from Investing Activities of $3.3 million as of Q3 2025, which was up 7460.9% from $12.6 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Cash from Investing Activities peaked at $152.9 million during Q2 2023, and registered a low of -$144.9 million during Q3 2021.
  • Over the past 5 years, Lyell Immunopharma's median Cash from Investing Activities value was $22.0 million (recorded in 2024), while the average stood at $13.6 million.
  • In the last 5 years, Lyell Immunopharma's Cash from Investing Activities crashed by 32806.06% in 2021 and then soared by 51118.35% in 2023.
  • Lyell Immunopharma's Cash from Investing Activities (Quarter) stood at -$73.9 million in 2021, then surged by 163.16% to $46.6 million in 2022, then plummeted by 315.85% to -$100.7 million in 2023, then skyrocketed by 153.14% to $53.5 million in 2024, then plummeted by 93.74% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $12.6 million for Q2 2025, and $69.5 million during Q1 2025.